However, these natural-derived STAT3/5 inhibitors have exhibited limited efficacy in clinical trials so far, and additional studies are required to clearly establish their utility as a monotherapy or in combination regimens with existing drugs for cancer patients. Here, STAT3 is linked to cancer.